cbdMD Achieves Self-Affirmed GRAS Status for Broad Spectrum CBD
Event summary
- cbdMD completed a self-affirmed Generally Recognized as Safe (GRAS) determination for its broad spectrum CBD, supporting safe daily consumption of up to 200 mg for healthy adults.
- The determination is based on years of peer-reviewed safety research, including studies in rodents, humans, and canines.
- An independent panel of expert toxicologists reviewed the scientific literature to support the GRAS conclusion.
- The milestone aligns with CMS's Substance Access Beneficiary Engagement Incentive and FDA's enforcement discretion for orally administered CBD products.
The big picture
cbdMD's GRAS determination positions it as a leader in evidence-based CBD wellness, aligning with broader industry shifts toward regulatory clarity and clinical integration. The milestone comes as policymakers increasingly endorse physician-guided access to hemp-derived CBD, signaling a new era of mainstream acceptance for cannabinoid products.
What we're watching
- Regulatory Tailwinds
- How CMS and FDA policies will shape the mainstream adoption of CBD in healthcare settings.
- Market Differentiation
- Whether cbdMD's GRAS status can solidify its leadership position in the hemp-derived wellness category.
- Product Expansion
- The pace at which cbdMD will leverage this determination to develop new product formats and applications.